ECRM_1170x120_1-10-22

Xolair (omalizumab) prefilled syringe

FDA approves Xolair (omalizumab) prefilled syringe for self-injection across all indications

FDA approves Xolair (omalizumab) prefilled syringe for self-injection across all indications

SOUTH SAN FRANCISCO, Calif.— Genentech announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair (omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe